Literature DB >> 20824475

Cancer systems biology.

Dana Faratian1, James L Bown, V Anne Smith, Simon P Langdon, David J Harrison.   

Abstract

Cancer is a complex and heterogeneous disease, not only at a genetic and biochemical level, but also at a tissue, organism, and population level. Multiple data streams, from reductionist biochemistry in vitro to high-throughput "-omics" from clinical material, have been generated with the hope that they encode useful information about phenotype and, ultimately, tumour behaviour in response to drugs. While these data stand alone in terms of the biology they represent, there is the enticing prospect that if incorporated into systems biology models, they can help understand complex systems behaviour and provide a predictive framework as an additional tool in understanding how tumours change and respond to treatment over time. Since these biological data are heterogeneous and frequently qualitative rather than quantitative, at the present time a single systems biology approach is unlikely to be effective; instead, different computational and mathematical approaches should be tailored to different types of data, and to each other, in order to test and re-test hypotheses. In time, these models might converge and result in usable tractable models which accurately represent human cancer. Likewise, biologists and clinicians need to understand what the requirements of systems biology are so that compatible data are produced for computational modelling. In this review, we describe some theoretical approaches (data-driven and process-driven) and experimental methodologies which are being used in cancer research and the clinical context where they might be applied.

Entities:  

Mesh:

Year:  2010        PMID: 20824475     DOI: 10.1007/978-1-60761-800-3_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  What can molecular pathology contribute to the management of renal cell carcinoma?

Authors:  Grant D Stewart; Fiach C O'Mahony; Thomas Powles; Antony C P Riddick; David J Harrison; Dana Faratian
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

Review 2.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

3.  Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic Cancer.

Authors:  Yi Tan; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2012-12-06

4.  The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma.

Authors:  Fiach C O'Mahony; Dana Faratian; James Varley; Jyoti Nanda; Marianna Theodoulou; Antony C P Riddick; David J Harrison; Grant D Stewart
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

5.  Systems biology approaches to decoding the genome of liver cancer.

Authors:  Ju-Seog Lee; Ji Hoon Kim; Yun-Yong Park; Gordon B Mills
Journal:  Cancer Res Treat       Date:  2011-12-27       Impact factor: 4.679

Review 6.  Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.

Authors:  David Henderson; Lesley A Ogilvie; Nicholas Hoyle; Ulrich Keilholz; Bodo Lange; Hans Lehrach
Journal:  Biotechnol J       Date:  2014-07-29       Impact factor: 4.677

Review 7.  Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.

Authors:  Hayley P Ellis; Mark Greenslade; Ben Powell; Inmaculada Spiteri; Andrea Sottoriva; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-11-16       Impact factor: 6.244

8.  Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma.

Authors:  Jiaheng Xie; Zhechen Zhu; Yuan Cao; Shujie Ruan; Ming Wang; Jingping Shi
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.